346 related articles for article (PubMed ID: 28966034)
1. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.
Braun CJ; Stanciu M; Boutz PL; Patterson JC; Calligaris D; Higuchi F; Neupane R; Fenoglio S; Cahill DP; Wakimoto H; Agar NYR; Yaffe MB; Sharp PA; Hemann MT; Lees JA
Cancer Cell; 2017 Oct; 32(4):411-426.e11. PubMed ID: 28966034
[TBL] [Abstract][Full Text] [Related]
2. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
[TBL] [Abstract][Full Text] [Related]
3. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
4. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
[TBL] [Abstract][Full Text] [Related]
6. EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Liu X; He J; Mao L; Zhang Y; Cui W; Duan S; Jiang A; Gao Y; Sang Y; Huang G
Exp Eye Res; 2021 Jan; 202():108286. PubMed ID: 33035554
[TBL] [Abstract][Full Text] [Related]
7. Exploiting the Hidden Treasure of Detained Introns.
Fu XD
Cancer Cell; 2017 Oct; 32(4):393-395. PubMed ID: 29017049
[TBL] [Abstract][Full Text] [Related]
8. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Banasavadi-Siddegowda YK; Russell L; Frair E; Karkhanis VA; Relation T; Yoo JY; Zhang J; Sif S; Imitola J; Baiocchi R; Kaur B
Oncogene; 2017 Jan; 36(2):263-274. PubMed ID: 27292259
[TBL] [Abstract][Full Text] [Related]
9. SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity.
Kim JH; Jeong K; Li J; Murphy JM; Vukadin L; Stone JK; Richard A; Tran J; Gillespie GY; Flemington EK; Sobol RW; Lim SS; Ahn EE
Nat Commun; 2021 Sep; 12(1):5551. PubMed ID: 34548489
[TBL] [Abstract][Full Text] [Related]
10. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
11. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
[TBL] [Abstract][Full Text] [Related]
12. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
13. LncRNA SNHG16 Functions as an Oncogene by Sponging MiR-4518 and Up-Regulating PRMT5 Expression in Glioma.
Lu YF; Cai XL; Li ZZ; Lv J; Xiang YA; Chen JJ; Chen WJ; Sun WY; Liu XM; Chen JB
Cell Physiol Biochem; 2018; 45(5):1975-1985. PubMed ID: 29529599
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
Dong Y; Song C; Wang Y; Lei Z; Xu F; Guan H; Chen A; Li F
Cell Signal; 2017 Jun; 34():55-65. PubMed ID: 28302565
[TBL] [Abstract][Full Text] [Related]
15. PRMT1 loss sensitizes cells to PRMT5 inhibition.
Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H
Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320
[TBL] [Abstract][Full Text] [Related]
16. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Han X; Li R; Zhang W; Yang X; Wheeler CG; Friedman GK; Province P; Ding Q; You Z; Fathallah-Shaykh HM; Gillespie GY; Zhao X; King PH; Nabors LB
J Neurooncol; 2014 May; 118(1):61-72. PubMed ID: 24664369
[TBL] [Abstract][Full Text] [Related]
17. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Gullà A; Hideshima T; Bianchi G; Fulciniti M; Kemal Samur M; Qi J; Tai YT; Harada T; Morelli E; Amodio N; Carrasco R; Tagliaferri P; Munshi NC; Tassone P; Anderson KC
Leukemia; 2018 Apr; 32(4):996-1002. PubMed ID: 29158558
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PRMT5 Attenuates Oxidative Stress-Induced Pyroptosis via Activation of the Nrf2/HO-1 Signal Pathway in a Mouse Model of Renal Ischemia-Reperfusion Injury.
Diao C; Chen Z; Qiu T; Liu H; Yang Y; Liu X; Wu J; Wang L
Oxid Med Cell Longev; 2019; 2019():2345658. PubMed ID: 31885778
[TBL] [Abstract][Full Text] [Related]
19. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Jensen-Pergakes K; Tatlock J; Maegley KA; McAlpine IJ; McTigue M; Xie T; Dillon CP; Wang Y; Yamazaki S; Spiegel N; Shi M; Nemeth A; Miller N; Hendrickson E; Lam H; Sherrill J; Chung CY; McMillan EA; Bryant SK; Palde P; Braganza J; Brooun A; Deng YL; Goshtasbi V; Kephart SE; Kumpf RA; Liu W; Patman RL; Rui E; Scales S; Tran-Dube M; Wang F; Wythes M; Paul TA
Mol Cancer Ther; 2022 Jan; 21(1):3-15. PubMed ID: 34737197
[TBL] [Abstract][Full Text] [Related]
20. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
